सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (HQ)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan, ITO, Kotla Road New Delhi – 110002
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/21/000090

To

M/s. Novo Nordisk India Pvt. Ltd.,
Plot No.32, 47-50, EPIP Area, Whitefield,
Bangalore, Karnataka–560066, India.

Sir,

With reference to your SUGAM application no.: GCT/CT04/FF/2021/27335 (GCT/90/21) dated 03-AUG-2021, please find enclosed herewith the permission in Form CT-06 for conduct of phase IIIa clinical trial titled, "**A 52-Week study comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 units/mL Combined with Insulin Aspart, both treatment arms with or without Oral Anti-diabetic Drugs, in Participants with Type 2 Diabetes Inadequately Controlled with Daily Basal Insulin (COMBINE-3)", vide Protocol Number:NN1535-4593, Version:2.0 dated 01-JUL-2021 and Protocol Addendum (India), Version:1.0 dated 21-DEC-2021** under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, that: -

1) **Firm should submit the revised Investigator Undertaking with India specific protocol addendum from all participating CT sites;**
2) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
3) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

   Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

   Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
4) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
5) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
6) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
7) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
8) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
9) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or

terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

10) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

11) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

12) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

13) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

14) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

15) Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

16) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

17) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

18) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

19) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

20) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b5874 8ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.01.06 15:13:56 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Novo Nordisk India Pvt. Ltd., Plot No. 32, 47 - 50, EPIP Area, Whitefield Bangalore (India) - 560066 to** conduct clinical trial of the new drug or investigational new drug as per **COMBINE-3 study Protocol Number: NN1535-4593, Version:2.0 dated 01-JUL-2021 and Protocol Addendum (India) Version 1.0 dated 21-DEC-2021** in the below mentioned clinical trial sites [As per Annexure].

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.01.06 15:14:05 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India) &
Central Licencing Authority

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	IcoSema 700 units/mL + 2 mg/mL (Insulin Icodec 700U/ml + Semaglutide 2.0 mg/ml)
Therapeutic class:	Anti-Diabetic
Dosage form:	Solution for injection
Composition:	Semaglutide = 2.0000 mg/ml In House specification Active Insulin Icodec = 4200.0000 nmol/ml In House Specification Active NaOH = 1.0000 q.s. U.S.P., E.P., J.P. Inactive HCl = 1.0000 q.s. U.S.P., E.P.,J.P. Inactive NaCl = 1.1700 mg/ml U.S.P., E.P., J.P. Inactive Sodium Chloride =1.1700 mg/ml U.S.P., E.P.,J.P. Inactive Metacresol = 1.0800 mg/ml E.P., U.S..P. Inactive Phenol = 5.6500 mg/ml U.S.P.,E.P.,J.P. Inactive Glycerol = 15.0000 mg/ml U.S.P., E.P.,J.P. Inactive Zinc Acetate = 101.0000 µg/ml U.S.P.,E.P.,J.P. Inactive Water for Injection = 1.0000 v/v U.S.P., E.P., J.P. Inactive
Indications:	Type 2 Diabetes inadequately controlled with daily basal insulin

Annexure:

Details of clinical trial site:

S. No.	Names and address of clinical trial site	Ethics committee details	Name of Investigator
1.	Christian Medical College and Hospital, Brown Road, Ludhiana, Punjab – 141008	Institutional Ethics Committee, C/o Principal Office, Christian Medical College & Hospital, Brown Road, Ludhiana, Punjab, India-141008	Dr. Jubbin Jagan Jacob
2.	Post Graduate Institute of Medical Education and Research (PGIMER), Department of Endocrinology, Nehru Hospital Extension Block, PGIMER, Chandigarh- 160012	Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research, Room No. 6006, IEC Office, 6th Floor PN Chuttani Block, Chandigarh - 160012	Dr. Ashu Rastogi
3.	Apollo Hospitals International Ltd, Plot no. 1a, GIDC Estate, Bhat, Gandhinagar, Gujarat 382428	Institutional Ethics Committee-Clinical Studies, Office of Institutional Ethics Committee, Site Office building, Near khodiyar maa temple, Parking area, Apollo Hospitals International Ltd, Plot no.1a, GIDC Estate, Bhat, Gandhinagar, Gujarat-382428	Dr. Goyal Ramesh Omprakash
4.	Swasthya Diabetes Care, 132 Feet Ring Road, Naranpura, Ahmedabad, Gujarat - 380013	Riddhi Medical Nursing Home IEC, Riddhi Medical Nursing Home A/101 Jalaram Plaza Jawahar Chowk, Maninagar Ahmedabad, Gujarat - 380008	Dr. Mayur Patel
5.	Nizams Institute of Medical Sciences, Endocrinology OPD, Old OPD Block, Punjagutta, Rd, Punjagutta, Hyderabad, Telangana - 500082	NIMS Institutional Ethics Committee (NIEC), Nizams Institute of medical sciences, Punjagutta Rd Punjagutta, Hyderabad, Telangana - 500082	Dr. Beatrice Anne M.
6.	Chellaram Diabetes Institute, 1st Floor, Lalani Quantum, NH-4, Opp. Calsoft Building, Bavdhan (Budruk), Pune-411021, Maharashtra	Chellaram Diabetes Institute – Institutional Ethics Committee, 1st Floor, Lalani Quantum, Pune-Bangalore National Highway no. 4. oppsite calsoft Building, Bavdhan (Budruk), Pune Maharashtra-411021	Dr. Unnikrishnan A. G.
7.	Sahyadri Super Speciality Hospital, 30-C, Erandvane, Karve Road, Pune-411004, Maharashtra, India Sahyadri Clinical Research and Development Center (Unit of Sahyadri HospitL) 33/34B, Makaranda, Bhave Path, Karve Road, Pune-411004, Maharashtra	Sahyadri Hospitals Pvt. Ltd., Ethics Committee, Sahyadri Clinical Research and Development Center, 33/34B, Makaranda, Bhave Path, Karve Road, Pune-411004, Maharashtra	Dr. Uday Phadke
8.	Department of Endocrinology Diabetes & Metabolism, 810, Christian Medical College, Vellore - 632004	Institutional Review Board-Ethics Committee - Silver, Carman Block, Christian Medical College, Bagayam, Vellore – 632002, Tamil Nadu, India	Dr. Nihal Thomas

9.	Diacon Hospital Pvt. Ltd, 359-360, 19th Main, 1st Block, Rajainagar, Bangalore-560010	Diacon Hospital Ethics Committee, Diacon Hospital Pvt. Ltd., 359-360, 19th Main, 1st Block, Rajajinagar Bangalore-560010	Dr. Aravind S. R.
10.	Madras Diabetes Research Foundation, No.4 Conran Smith Road, Gopalapuram, Chennai-600086	Institutional Ethics Committee of Madras Diabetes Research Foundation, No.4, Conran Smith Road, Gopalapuram, Chennai-600086	Dr. Viswanathan Mohan

****